Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A C Moses

Showing results (71-80 of 90) with videos related to

Pageof 9
Sort By:
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 1, 1995
Treatment with growth hormone and IGF-I in growing rats increases bone mineral content but not bone mineral densityH N Rosen, V Chen, A Cittadini, et al.
The Journal of Clinical Endocrinology and Metabolism|October 1, 1981
Bromocriptine therapy in acromegaly: use in patients resistant to conventional therapy and effect on serum levels of somatomedin CA C Moses, M E Molitch, C T Sawin, et al.
Calcified Tissue International|September 1, 1994
Subregion analysis of the rat femur: a sensitive indicator of changes in bone density following treatment with thyroid hormone or bisphosphonatesH N Rosen, V L Middlebrooks, E K Sullivan, et al.
Calcified Tissue International|January 1, 1994
Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnoverH N Rosen, R Dresner-Pollak, A C Moses, et al.
Calcified Tissue International|February 1, 2000
Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapyH N Rosen, A C Moses, J Garber, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1980
Increased levels of multiplication-stimulating activity, an insulin-like growth factor, in fetal rat serumA C Moses, S P Nissley, P A Short, et al.
The Journal of Clinical Endocrinology and Metabolism|September 1, 1993
Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humansH N Rosen, A C Moses, C Gundberg, et al.
Endocrinology|April 1, 1995
Bone density is normal in male rats treated with finasterideH N Rosen, S Tollin, R Balena, et al.
Circulation Research|July 22, 1998
Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca2+ through a wortmannin-sensitive pathway: studies in rat and ferret isolated musclesA Cittadini, Y Ishiguro, H Strömer, et al.
Diabetes|February 1, 1994
Prevalence of mutations in the insulin receptor gene in subjects with features of the type A syndrome of insulin resistanceD E Moller, O Cohen, Y Yamaguchi, et al.
Pageof 9

Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 1, 1995
Treatment with growth hormone and IGF-I in growing rats increases bone mineral content but not bone mineral densityH N Rosen, V Chen, A Cittadini, et al.
The Journal of Clinical Endocrinology and Metabolism|October 1, 1981
Bromocriptine therapy in acromegaly: use in patients resistant to conventional therapy and effect on serum levels of somatomedin CA C Moses, M E Molitch, C T Sawin, et al.
Calcified Tissue International|September 1, 1994
Subregion analysis of the rat femur: a sensitive indicator of changes in bone density following treatment with thyroid hormone or bisphosphonatesH N Rosen, V L Middlebrooks, E K Sullivan, et al.
Calcified Tissue International|January 1, 1994
Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnoverH N Rosen, R Dresner-Pollak, A C Moses, et al.
Calcified Tissue International|February 1, 2000
Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapyH N Rosen, A C Moses, J Garber, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1980
Increased levels of multiplication-stimulating activity, an insulin-like growth factor, in fetal rat serumA C Moses, S P Nissley, P A Short, et al.
The Journal of Clinical Endocrinology and Metabolism|September 1, 1993
Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humansH N Rosen, A C Moses, C Gundberg, et al.
Endocrinology|April 1, 1995
Bone density is normal in male rats treated with finasterideH N Rosen, S Tollin, R Balena, et al.
Circulation Research|July 22, 1998
Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca2+ through a wortmannin-sensitive pathway: studies in rat and ferret isolated musclesA Cittadini, Y Ishiguro, H Strömer, et al.
Diabetes|February 1, 1994
Prevalence of mutations in the insulin receptor gene in subjects with features of the type A syndrome of insulin resistanceD E Moller, O Cohen, Y Yamaguchi, et al.
Pageof 9